Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease
نویسندگان
چکیده
منابع مشابه
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
IMPORTANCE Hyperkalemia is a potentially life-threatening condition predominantly seen in patients treated with renin-angiotensin-aldosterone system (RAAS) inhibitors with stage 3 or greater chronic kidney disease (CKD) who may also have diabetes, heart failure, or both. OBJECTIVES To select starting doses for a phase 3 study and to evaluate the long-term safety and efficacy of a potassium-bi...
متن کاملPatiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which increases mortality and can lead to renin-angiotensin-aldosterone system inhibitor (RAASi) dose reduction or discontinuation. Patiromer, a nonabsorbed potassium binder, has been shown to normalize serum potassium in patients with CKD and hyperkalemia on RAASi. Here, patiromer's onset of action was determined in p...
متن کاملthe effect of oxytetracycline on serum calcium, phosphorus and magnesium in cattle
نتایج این مطالعه نشان می دهد که مقدار کلسیم (یونیزه و تام)، منیزیم و فسفر به طور معنی داری تغییر پیدا کرد به جزء مقدار کلسیم تام و منیزیم در روش داخل عضلانی که تغییر معنی داری نداشته است. بر اساس نتایج این مطالعه می توان نتیجه گیری کرد که اکسی تتراساکلین بر روی مقادیر سرمی کلسیم و منیزیم تأثیر می گذارد باید مقدار این کاتیون ها در بیماران، در هنگامی که اکسی تتراسایکلین استفاده می شود مورد توجه ق...
15 صفحه اولPatiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
BACKGROUND Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium levels of...
متن کاملEffectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
OBJECTIVE Recurrent hyperkalemia frequently limits use of renin-angiotensin-aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD) patients with hypertension, diabetes, and/or heart failure. Patiromer is a sodium-free, nonabsorbed potassium (K)-binding polymer approved by the US Food and Drug Administration for the treatment of hyperkalemia. This post-hoc analysis of OPAL-HK exam...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA
سال: 2015
ISSN: 0098-7484
DOI: 10.1001/jama.2015.7446